Expert Perspective on the Evolving Standard of Care in Biliary Tract Cancers

February 2022 Vol 13, No 2


Erin Burns, PhD

Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert keynote perspective at the 3rd Annual Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangiocarcinoma (CCA), with liquid biopsy becoming the tool of choice for genomic profiling in biliary tract cancers.

Dr Borad discussed current global approaches to CCA from a personalized medicine point of view. “The human model system is truly maybe the best place to start and end, and this would be considered bedside-to-bench research,” he said.

Integrated sequencing allows for the investigation of several aspects of disease at once and a comprehensive view of the disease, including germline analysis, therapy selection, pharmacogenomics, clonal evolution, disease prognosis, and monitoring response to therapy.

Identifying the disease driver may be done through multiplatform concordance, mutation transcript–specific expression, heuristic knowledge, ranking of events, and target hyperselection. The prevalence of FGFR2 fusions in CCA is approximately 10%, almost exclusively in intrahepatic CCA. The patient-derived xenograft model can be used to identify the potential benefits and the relative efficacy of drugs, he explained.

“Working with colleagues in the radiation department, we have been trying to identify mutation signatures, using Fourier transform–based methods, what we would call radiomics, machine learning, or artificial intelligence, to see if we could identify those patients, or at least enrich very quickly, so we know if we have a patient with an FGFR2 fusion on our hands or not,” said Dr Borad. “And you can apply the same understanding to other mutations, such as IDH1/2 or KRAS.”

When we manage driver mutations with drugs such as pemigatinib, tumor shrinkage has been seen in up to 80% of cases. These responses have been semidurable, so the current unmet need is how to keep these responses durable, or how to overcome resistance, Dr Borad said.

He explained that tumor evolution is clearly common, and oncologists have to analyze it comprehensively and often to stay on top of the treatment. Whole-genome sequencing and other “omics” assessment should also be done; however, cost is a limitation. The analysis should be done at every decision point. As an initial step toward adopting this approach, comprehensive analysis may be completed at the initial diagnosis, but the compromise may be somewhere in the middle.

The ERRFI1 gene (or MIG-6) is a regulator of multiple pathways, such as EGFR or MET. Treating patients with erlotinib led to reduced tumor volume at 3 months.

Microsatellite instability-high is a targetable biomarker, with highly durable response rates after treatment in solid tumors. Mutational burden is variable across biliary tract cancers. Very deep and durable responses have been seen in patients with mismatch repair deficiency (dMMR) who received PD-1 blockade therapy. However, some patients do not respond to this therapy. “Studying these heterogeneities will be key to our understanding of how we approach these problems,” said Dr Borad.

Liquid biopsy may be used for target (or biomarker) identification, prognostication, dMMR detection, and response assessment in the next year or two. The benefits of liquid biopsy include speed, minimal invasiveness, ability to complete serial analysis without harm, and possibly improved representation of tumor heterogeneity, and it may be used to detect early resistance to therapy.

How can we select therapy better to increase the likelihood of response? Dr Borad suggested that tumor organoids and ex vivo therapy models may be incorporated for clinical decision enhancement as predictive tools.

Reprinted by permission of CCA News, Copyright © 2021 Engage Healthcare Communications, LLC.

February Is Cholangiocarcinoma Awareness Month

In recognition of Cholangiocarcinoma Awareness Month, the Journal of Oncology Navigation & Survivorship is pleased to present an update on the current standard of care for biliary tract cancers.


The 4th Annual Cholangiocarcinoma Summit will be held October 13-15, 2022, at the Gaylord Rockies Convention Center in Aurora, CO. To learn more, please visit

Meet the 2021 Nurse ONE Award Winner!

The Cholangiocarcinoma Oncology Nurse of Excellence (ONE) Award recognizes an oncology nurse for their outstanding contributions to nursing practice, patient care, or education in the cholangiocarcinoma field in 2021.

Jane Zorzi, BSN, RN

After much consideration, a winner of the first annual Cholangiocarcinoma ONE Award has been chosen based on your peer votes for the 4 finalists. Each of the finalists were outstanding, but this individual stood out for her leadership and compassion and for her commitment to patient care. Please join us in congratulating your choice for the 2021 Cholangiocarcinoma ONE Award, Jane Zorzi, BSN, RN, oncology nurse at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Liver and Biliary Cancer Multidisciplinary Clinic. Jane Zorzi received a plaque to recognize her contribution to cholangiocarcinoma oncology nursing, as well as a donation to the Cholangiocarcinoma Foundation in her name. Thank you to the supporter of the Cholangiocarcinoma ONE Award, AstraZeneca.

Related Articles
First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)
Special Issues and Supplements
Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma
In 2023, much research has been conducted on the treatment of biliary tract cancer (BTC), with an emphasis on novel targeted therapies and combination strategies. Important advances in treatment for patients with BTC were presented at society conferences such as the American Society of Clinical Oncology (ASCO), ASCO GI, and European Society for Medical Oncology.
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State